Apogee Therapeutics (APGE) Operating Expenses (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Operating Expenses of $82.8 million for Q1 2026, up 31.18% year-over-year from $63.1 million in Q1 2025, and up 6.04% quarter-over-quarter from $78.1 million in Q4 2025.
Apogee Therapeutics (APGE) Operating Expenses (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Operating Expenses for 5 consecutive years, with $82.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 31.18% year-over-year to $82.8 million; the TTM figure through Mar 2026 stood at $305.3 million (up 26.26% YoY), while the FY2025 annual figure was $285.6 million, up 31.69% from the prior year.
- Operating Expenses rose to $82.8 million in Q1 2026 per APGE's latest filing, from $78.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $82.8 million in Q1 2026 and bottomed at $1.8 million in Q2 2022.
- Historically, Operating Expenses has averaged $44.0 million across 5 years, with a median of $41.2 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Expenses jumped 939.92% — and 2025, when it rose 2.87%.
- Apogee Therapeutics' Operating Expenses stood at $14.1 million in 2022, then soared by 163.53% to $37.2 million in 2023, then surged by 104.23% to $75.9 million in 2024, then climbed by 2.87% to $78.1 million in 2025, then advanced by 6.04% to $82.8 million in 2026.
- Business Quant data shows APGE's Operating Expenses at $82.8 million in Q1 2026, $78.1 million in Q4 2025, and $71.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | 96.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.00 Mn |
| Mar 31, 2026 | 82.77 Mn |
| Dec 31, 2025 | 78.06 Mn |
| Sep 30, 2025 | 71.28 Mn |
| Jun 30, 2025 | 73.17 Mn |
| Mar 31, 2025 | 63.10 Mn |
| Dec 31, 2024 | 75.88 Mn |
| Sep 30, 2024 | 58.69 Mn |
| Jun 30, 2024 | 44.12 Mn |
| Mar 31, 2024 | 38.18 Mn |
| Dec 31, 2023 | 37.16 Mn |
| Sep 30, 2023 | 24.31 Mn |
| Jun 30, 2023 | 18.89 Mn |
| Mar 31, 2023 | 12.66 Mn |
| Dec 31, 2022 | 14.10 Mn |
| Sep 30, 2022 | 10.51 Mn |
| Jun 30, 2022 | 1.82 Mn |